# Financial Results for FY2022 Second Quarter 

(April 1, 2022 - September 30, 2022)

November 1, 2022
SUMITOMO CHEMICAL

## (Cautionary Statement)

Statements made in this material with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace;
Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

## Contents

1. Consolidated Financial Results for FY2022 Second Quarter
Key Points of Financial Results ..... 4
Financial Summary ..... 5
Sales Revenue by Business Segment ..... 6
Core Operating Income by Business Segment ..... 7
Core Operating Income Analysis by Business Segment ..... 8
Breakdown of Non-recurring Items ..... 13
Consolidated Balance Sheets ..... 14
Consolidated Statements of Cash Flows ..... 15
2. Outlook for FY2022
Key Points of Outlook ..... 17
Performance Forecast for FY2022 ..... 18
Sales Revenue and Core Operating Income by Business Segment ..... 19
Reference
Costs and Expenses etc. ..... 21
Capital Expenditures
by Business Segment ..... 22
Depreciation and Amortization
by Business Segment ..... 23
Research \& Development Expenses by Business Segment ..... 24
Sales Revenue
by Business Segment (Quarterly) ..... 25
Core Operating Income by Business Segment (Quarterly) ..... 26
Sales Revenue Analysis by Business Segment ..... 27
Major Group Companies ..... 30
Crop Protection Product Sales by Region ..... 31

## 1. Consolidated Financial Results for FY2022 Second Quarter

## First Half FY2022 Business Environment

## Economic Conditions

- Because of the weakening yen, the profitability of exports and overseas businesses improved
- On the other hand, because of the crisis in Ukraine and high inflation, the sharp rise in raw material and fuel prices has put pressure on business results


## Business Environment

| Petrochemicals/ <br> Raw Materials | Downstream demand was weak, and the market for petrochemical products was stagnant <br> On the other hand, because the market for refined petroleum products was tight, <br> Petro Rabigh's first-half results are strong |
| :---: | :--- |
| Automobiles | Auto production continued to decline because of shortages in semiconductors <br> and the lockdown in China |
| Displays | Because stay-at-home demand has fallen and consumer sentiment has soured <br> due to inflation concerns, demand for display panels sharply declined |
| Semiconductors | Strong demand continued with the expansion of the market |
| Methionine | In addition to strong demand for crop protection products, higher selling prices in <br> South America made a solid contribution to performance in the period |
| Market prices improved, but the rise of raw material and fuel prices outpaced the |  |
| Pharmaceuticals | Sales of LATUDA ® continued to be strong |

## Financial Summary

|  |  |  |  | ons of yen |
| :---: | :---: | :---: | :---: | :---: |
|  | 2Q FY2021 | 2Q FY2022 | Variance | Ratio |
| Sales revenue | 1,325.2 | 1,528.6 | 203.4 | 15.3\% |
| Core operating income | 148.9 | 115.6 | -33.3 | -22.3\% |
| Of which equity in earnings | 27.2 | 29.9 | 2.6 | - |
| Non-recurring items | -4.6 | -55.1 | -50.4 | - |
| Operating income | 144.3 | 60.6 | -83.7 | -58.0\% |
| Finance income/expenses | 2.5 | 66.2 | 63.7 | - |
| Of which gain/loss on foreign currency transactions | 6.0 | 82.1 | 76.2 | - |
| Income tax expenses | -39.0 | -53.7 | -14.7 | - |
| Net income attributable to non-controlling interests | -18.9 | 8.0 | 26.9 | - |
| Net income attributable to owners of the parent | 88.9 | 81.1 | -7.8 | -8.8\% |
| ROE | 8.5\% | 6.2\% |  |  |
| Exchange rate (yen/\$) | 109.81 | 134.03 |  |  |
| Naphtha price (yen/KL) | 50,600 | 83,600 |  |  |
| Overseas sales revenue ratio | 67.1\% | 70.4\% |  |  |

## Sales Revenue by Business Segment



## Analysis of Variance +165.6



SUMITOMO CHEMICAL

## Core Operating Income by Business Segment

Unit: Billions of yen
$\left.\begin{array}{l|r|r|r|r|r|r} & \text { 2Q FY2021 } & \text { 2Q FY2022 } & \text { Variance } & \begin{array}{c}\text { Shipping } \\ \text { Price } \\ \text { variance }\end{array} \\ \text { volume } \\ \text { variance } \\ \text { and other }\end{array}\right)$

## Analysis of Variance



## Essential Chemicals \& Plastics

## Core Operating Income Total $¥ 23.3$ billion (-18.8 from 2Q FY2021)



Price variance

## Volume

 variance etc.Terms of trade have deteriorated because increases in sales prices have not kept up with increases in raw material and fuel prices for products such as synthetic resins, MMA, and various industrial chemicals.

Shipments decreased due to a drop in demand, particularly in automotive applications, despite improvements in operations at Petro Rabigh

## Energy \& Functional Materials

## Core Operating Income Total $¥ 13.4$ billion ( +0.9 from 2Q FY2021)



> Price variance

Volume variance etc.

For aluminum and cathode materials, terms of trade improved in line with market prices.
For other products, such as resorcinol and synthetic rubber, terms of trade deteriorated due to increases in raw material and fuel prices.

In addition to continued strong shipments of lithium-ion secondary battery separators, net income from exports increased due to the weak yen.

## IT-related Chemicals

## Core Operating Income Total $¥ 26.4$ billion (-3.1 from 2Q FY2021)



| Price <br> Variance |  | Displays |
| :---: | :---: | :---: |
|  | Selling prices fell for polarizing film and touch sensor panels |  |

## SUMITOMO CHEMICAL

## Health \& Crop Sciences

## Core Operating Income Total $¥ 36.3$ billion (+17.9 from 2Q FY2021)



| Price variance | Crop Protection | Improved terms of trade due to increased sales prices for generics in South America |
| :---: | :---: | :---: |
|  | Methionine | Terms of trade deteriorated due to increased raw material and fuel prices, despite improved market prices |
| Cost variance | Crop Protection | Expenses relating to business expansion increased, such as the immediate launch of INDIFLIN ${ }^{\circledR}$ and development expenses for new pipeline products |
| Volume variance etc. | Crop Protection <br> Overall | Increased shipments in South America and India Increased net income on exports and profit from foreign currency conversion due to the weak yen |

SUMITOMO CHEMICAL

## Pharmaceuticals

## Core Operating Income Total $¥ \mathbf{2 5 . 2}$ billion (-24.8 from 2Q FY2021)



| Price variance | Sales prices decreased due to the revisions to drug prices in Japan |
| :---: | :---: |
| Cost variance | Increases in sales expenses and general management expenses in the Sumitovant Group related to sales promotion activities for products such as ORGOVYX® and GEMTESA® |
| Volume variance etc. | In addition to sales growth of products such as LATUDA ®, ORGOVYX®, and GEMTESA® in North America, a one-time gain was recorded on the licensing contract for sales of ORGOVYX® in Europe. On the other hand, there had been a lump-sum revenue for the collaboration and license agreement for joint development and commercialization in the same quarter last year. |

SUMITOMO CHEMICAL

## Breakdown of Non-recurring Items

Unit: Billions of yen

|  | 2Q FY2021 | 2Q FY2022 | Variance |
| :--- | :---: | :---: | :---: |
| Impairment loss | -1.6 | $\mathbf{- 5 4 . 5}$ | -52.9 |
| Restructuring charges | -3.0 | $\mathbf{- 8 . 4}$ | -5.4 |
| Gain on sale of property, plant and equipment | 0.2 | $\mathbf{3 . 5}$ | 3.4 |
| Changes in fair value of contingent consideration | -0.1 | $\mathbf{1 . 3}$ | 1.4 |
| Others | -0.0 | $\mathbf{3 . 1}$ | 3.1 |
| Non-recurring items | $\mathbf{- 4 . 6}$ | $\mathbf{- 5 5 . 1}$ | $\mathbf{- 5 0 . 4}$ |

## Consolidated Balance Sheets

|  |  |  |  | Unit: Billions of yen |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 31-Mar-22 | 30-Sep-22 | Variance |  | 31-Mar-22 | 30-Sep-22 | Variance |
| Current assets | 1,812.6 | 2,140.5 | 327.8 | Liabilities | 2,606.2 | 2,793.4 | 187.2 |
| Cash and cash equivalents | 365.4 | 486.0 | 120.6 | Trade and other payables | 551.6 | 635.3 | 83.8 |
| Trade and other receivables | 720.4 | 738.5 | 18.0 | Interest-bearing Liabilities | 1,350.5 | 1,392.9 | 42.4 |
| Inventories | 651.4 | 805.2 | 153.9 | Others | 704.1 | 765.2 | 61.1 |
| Others | 75.4 | 110.8 | 35.4 | Equity | 1,702.0 | 1,888.7 | 186.7 |
| Non-current assets | 2,495.5 | 2,541.6 | 46.0 | Shareholders' equity | 1,082.8 | 1,147.4 | 64.6 |
| Property, plant and equipment | 823.0 | 855.8 | 32.8 | Other components of equity | 135.3 | 232.1 | 96.8 |
| Goodwill and Intangible assets | 715.6 | 751.4 | 35.8 | Non-controlling interests | 483.9 | 509.2 | 25.3 |
| Others | 956.9 | 934.4 | -22.5 |  |  |  |  |
| Total | 4,308.2 | 4,682.0 | 373.9 | Total | 4,308.2 | 4,682.0 | 373.9 |
|  |  |  |  | Equity attributable to owners of parent to total assets | 28.3\% | 29.5\% | 1.2\% |
|  |  |  |  | D/E ratio (times) | 0.8 | 0.7 | -0.1 |

## Consolidated Statements of Cash Flows

|  | Unit: Billions of yen |  |  |
| :---: | :---: | :---: | :---: |
|  | 2Q FY2021 | 2Q FY2022 | Variance |
| Cash flows from operating activities | 77.2 | 83.5 | 6.3 |
| Cash flows from investing activities | -65.2 | 15.6 | 80.7 |
| Free cash flows | 12.0 | 99.1 | 87.0 |
| Cash flows from financing activities | -27.1 | -24.7 | 2.5 |
| Effect of exchange rate changes on cash and cash equivalents | 1.0 | 46.2 | 45.2 |
| Net change in cash and cash equivalents | -14.1 | 120.6 | 134.7 |
| Cash and cash equivalents at end of period | 346.8 | 486.0 | 139.2 |

## 2. Outlook for FY2022

## Second Half FY2022 Outlook for the Business Environment

## Economic Conditions

There are concerns about a recession because of high raw material and fuel prices and because of the policy of countries to raise interest rates

## Changes in the Business Environment, First Half $=$ Second Half

| Petrochemicals/ <br> Raw Materials | For Petro Rabigh, tight market conditions for refined petroleum products are <br> expected to ease |
| :--- | :--- | :--- |
| Automobiles | We anticipate a recovery in production after a sluggish period due to <br> shortage in semiconductor |
| Sisplays | We anticipate a sharp decline in display-related demand due to a prolonged <br> inventory adjustment period for display panels |
| Semiconductors | We anticipate an expansion of the market, but there are signs of <br> slowdown partly in memory markets |
| Crop Protection | Full-scale sales of new products will start in South America. <br> We anticipate a period of solid demand in North America and Japan. |
| Methionine | Facing a severe business environment due to raw material prices <br> remaining high |
|  | We are coming up on the loss of exclusivity for LATUDA ®, <br> but we are focusing on expanding the sales of new products |

## Performance Forecast for FY2022



## Sales Revenue and Core Operating Income by Business Segment 19

Unit: Billions of yen

|  | Sales revenue |  |  | Core operating income |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Previous <br> Forecast | Revised <br> Forecast | Variance | Previous <br> Forecast | Revised <br> Forecast | Variance |
| Essential Chemicals \& Plastics | 1,120.0 | 960.0 | -160.0 | 41.0 | 0.0 | -41.0 |
| Energy \& Functional Materials | 340.0 | 390.0 | 50.0 | 18.0 | 20.0 | 2.0 |
| IT-related Chemicals | 480.0 | 465.0 | -15.0 | 61.0 | 51.0 | -10.0 |
| Health \& Crop Sciences | 540.0 | 645.0 | 105.0 | 47.5 | 77.0 | 29.5 |
| Pharmaceuticals | 580.0 | 630.0 | 50.0 | 33.0 | 36.0 | 3.0 |
| Others \& Adjustments | 60.0 | 90.0 | 30.0 | -0.5 | 6.0 | 6.5 |
| Total | 3,120.0 | 3,180.0 | 60.0 | 200.0 | 190.0 | -10.0 |

## Reference

## Cost and Expenses etc.

|  | Unit: Billions of yen |  |  |
| :---: | :---: | :---: | :---: |
|  | 2Q FY2021 | 2Q FY2022 | Variance |
| Capital Expenditures | 51.0 | 69.1 | 18.0 |
| Depreciation and Amortization | 77.7 | 85.8 | 8.1 |
| Research \& Development Expenses | 83.8 | 93.4 | 9.7 |
| Number of Employees (as of September 30, 2022) | 34,973 | 34,654 | -319 |

## Capital Expenditures by Business Segment

Unit: Billions of yen

|  | 2Q FY2021 | 2Q FY2022 | Variance |
| :---: | :---: | :---: | :---: |
| Essential Chemicals \& Plastics | 10.2 | 15.5 | 5.3 |
| Energy \& Functional Materials | 11.8 | 11.7 | -0.1 |
| IT-related Chemicals | 6.1 | 13.4 | 7.3 |
| Health \& Crop Sciences | 8.5 | 13.1 | 4.6 |
| Pharmaceuticals | 8.5 | 6.5 | -2.1 |
| Others \& Adjustments | 5.9 | 9.0 | 3.1 |
| Total | 51.0 | 69.1 | 18.0 |

## Depreciation and Amortization by Business Segment

Unit: Billions of yen

|  | 2Q FY2021 | 2Q FY2022 | Variance |
| :--- | ---: | ---: | ---: |
| Essential Chemicals \& Plastics | 13.4 | 14.5 | 1.0 |
| Energy \& Functional Materials | 9.4 | 9.4 | -0.0 |
| IT-related Chemicals | 13.8 | 13.7 | -0.1 |
| Health \& Crop Sciences | 13.4 | $\mathbf{1 4 . 3}$ | 0.9 |
| Pharmaceuticals | 19.6 | $\mathbf{2 3 . 7}$ | 4.2 |
| Others \& Adjustments | 8.1 | $\mathbf{1 0 . 3}$ | 2.1 |
| Total | 77.7 | $\mathbf{8 5 . 8}$ | 8.1 |

## Research \& Development Expenses by Business Segment

|  | Unit: Billions of yen |  |  |
| :---: | :---: | :---: | :---: |
|  | 2Q FY2021 | 2Q FY2022 | Variance |
| Essential Chemicals \& Plastics | 3.4 | 3.5 | 0.1 |
| Energy \& Functional Materials | 3.8 | 4.4 | 0.5 |
| IT-related Chemicals | 9.6 | 9.8 | 0.2 |
| Health \& Crop Sciences | 12.2 | 14.5 | 2.4 |
| Pharmaceuticals | 46.9 | 51.8 | 4.9 |
| Others \& Adjustments | 7.9 | 9.4 | 1.6 |
| Total | 83.8 | 93.4 | 9.7 |

## Sales Revenue by Business Segment (Quarterly)

|  | FY2021 |  |  |  | FY2022 |  | FY2022 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 1st Half | 2nd Half (Forecast) |
| Essential Chemicals \& Plastics | 199.5 | 200.0 | 225.5 | 217.6 | 238.6 | 228.7 | 467.3 | 492.7 |
| Energy \& Functional Materials | 74.4 | 74.1 | 78.2 | 89.7 | 86.4 | 87.1 | 173.5 | 216.5 |
| IT-related Chemicals | 109.3 | 118.4 | 124.4 | 121.7 | 114.7 | 107.5 | 222.2 | 242.8 |
| Health \& Crop Sciences | 103.1 | 106.4 | 121.5 | 142.8 | 152.6 | 141.3 | 293.9 | 351.1 |
| Pharmaceuticals | 139.2 | 170.4 | 146.7 | 135.4 | 167.7 | 166.7 | 334.4 | 295.6 |
| Others \& Adjustments | 13.6 | 17.0 | 16.4 | 20.3 | 14.2 | 23.0 | 37.2 | 52.8 |
| Total | 639.0 | 686.2 | 712.7 | 727.4 | 774.1 | 754.4 | 1,528.6 | 1,651.4 |

## Core Operating Income by Business Segment (Quarterly)

Unit: Billions of yen

|  | FY2021 |  |  |  | FY2022 |  | FY2022 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 1st Half | 2nd Half (Forecast) |
| Essential Chemicals \& Plastics | 23.8 | 18.2 | 10.0 | 1.5 | 10.0 | 13.3 | 23.3 | -23.3 |
| Energy \& Functional Materials | 6.7 | 5.9 | 6.1 | 1.4 | 6.6 | 6.8 | 13.4 | 6.6 |
| IT-related Chemicals | 13.5 | 16.0 | 16.4 | 11.9 | 15.8 | 10.7 | 26.4 | 24.6 |
| Health \& Crop Sciences | 10.3 | 8.2 | 9.4 | 14.4 | 21.9 | 14.4 | 36.3 | 40.7 |
| Pharmaceuticals | 9.6 | 40.3 | 12.5 | -0.7 | 14.1 | 11.1 | 25.2 | 10.8 |
| Others \& Adjustments | -2.3 | -1.4 | 2.5 | 0.6 | -4.3 | -4.8 | -9.0 | 15.0 |
| Total | 61.7 | 87.2 | 56.8 | 29.1 | 64.1 | 51.5 | 115.6 | 74.4 |

## Sales Revenue Analysis by Business Segment



## Sales Revenue Analysis by Business Segment



## Sales Revenue Analysis by Business Segment

## Pharmaceuticals

## Sales Revenue



Total $¥ 334.4$ billion ( +24.9 from 2Q FY2021)
Sales price $\quad$ Revisions to drug prices in Japan

- Increased shipments of Latuda®, Orgovyx®, Gemtesa®, etc., in North America
- Recorded one-time revenues due to sales license contract for Orgovyx® in Europe
- there had been a lump-sum revenue for the collaboration and license agreement for joint development and commercialization in the same quarter last year.


## Major Group Companies

| Company | Sales Revenue |  | Profit Trends |
| :---: | :---: | :---: | :---: |
|  | 2Q FY2021 | 2Q FY2022 |  |
| The Polyolefin Company (Singapore) <br> (Millions of USD) | 600 | 601 | A deterioration in profit margins |
| Petrochemical Corporation of Singapore <br> (Millions of USD) | 1,307 | 1,432 | A deterioration in profit margins |
| Rabigh Refining and Petrochemical Company <br> (Millions of SAR) | 21,245 | 32,502 | Improved margins on oil refining |
| Dongwoo Fine-Chem <br> (Billions of KRW) | 1,242.6 | 1,106.1 | Decrease due to lower sales volume of display-related materials |
| Valent U.S.A. and Subsidiaries <br> (Millions of USD) | 352 | 346 | Decrease in profit due to higher planned expenses |

## Crop Protection Product Sales by Region

Unit; Billions of yen

|  | FY2021 2nd Quarter | FY2022 <br> 2nd Quarter | Difference | Reasons for Change |
| :---: | :---: | :---: | :---: | :---: |
| Japan | 29.5 | 31.0 | 1.5 |  |
| North America | 22.8 | 26.1 | 3.3 | - Foreign currency conversion variance |
| Central \& South America | 55.1 | 115.2 | 60.1 | - Foreign currency conversion variance <br> - Increase in shipments |
| Asia (including India) | 27.0 | 37.2 | 10.2 | - Foreign currency conversion variance <br> - Increase in shipments in India |
| Europe \& Others | 9.2 | 10.6 | 1.4 | Foreign currency conversion variance Increase in shipments in Europe |
| Total | 143.6 | 220.1 | 75.0 |  |

